We have a well balanced portfolio of novel drugs directed toward diseases that represent significant unmet medical need.

On March 9, 2011, HGS and GlaxoSmithKline PLC (GSK) announced FDA approval of BENLYSTA® (belimumab) for the treatment of autoantibody-positive adult patients with active, systemic lupus erythematosus who are receiving standard therapy. BENLYSTA is the first new approved drug for lupus in more than 50 years.

In May 2009, we submitted a BLA to the FDA for raxibacumab for the treatment of inhalation anthrax. We received a Complete Response Letter in November 2009 and continue to work closely with the FDA to obtain approval for raxibacumab.

Right behind these late-stage products is an emerging mid-stage pipeline, focused on immunology and oncology and including potential additional indications for BENLYSTA. We also have substantial financial rights to a number of products in the GSK clinical pipeline. GSK is currently conducting Phase 3 clinical trials of darapladib in men and women with chronic coronary heart disease and albiglutide in patients with type 2 diabetes mellitus.

1. Initiation of Phase 3 trial in Asia planned 2011 2. Initiation of Phase 3 trial of subcutaneous formulation planned 2011 3. Sales to Strategic National Stockpile under U.S. Government Contract 4. Initiation of Phase 2 trial planned 2011 5. Rights acquired March 2011 from FivePrime Therapeutics